DDR defects, including those affecting BRCA1/2, are related to greater tumor mutational burden in tumors, including ovarian cancer and NSCLC [59,60], contributing to increase the amount of tumor-specific neoantigens, both valuable biomarkers for predicting the efficacy of ICI therapy, in combination with other indicators [61,62,63,64,65,66,67,68]. The gene discussed is BRCA1; the disease is ovarian carcinoma.